{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:25:25Z","timestamp":1790987125588,"version":"4.1.0"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"NCI\/NIH","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["P50 CA257881-01A1"],"award-info":[{"award-number":["P50 CA257881-01A1"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40265-026-02295-0","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:23:44Z","timestamp":1771867424000},"page":"507-532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6187-4655","authenticated-orcid":false,"given":"Michael S.","family":"May","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-3102","authenticated-orcid":false,"given":"Wungki","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2295_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"2295_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","volume":"31","author":"AM Varghese","year":"2025","unstructured":"Varghese AM, Perry MA, Chou JF, et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat Med. 2025;31:466\u201377. https:\/\/doi.org\/10.1038\/s41591-024-03362-3.","journal-title":"Nat Med"},{"key":"2295_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/bjc.2014.215","volume":"111","author":"S Eser","year":"2014","unstructured":"Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014;111:817\u201322. https:\/\/doi.org\/10.1038\/bjc.2014.215.","journal-title":"Br J Cancer"},{"key":"2295_CR4","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2103695.","journal-title":"N Engl J Med"},{"key":"2295_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387:120\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2204619.","journal-title":"N Engl J Med"},{"key":"2295_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1252516","volume":"13","author":"L Qunaj","year":"2023","unstructured":"Qunaj L, May MS, Neugut AI, Herzberg BO. Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer. Front Oncol. 2023;13:1252516. https:\/\/doi.org\/10.3389\/fonc.2023.1252516.","journal-title":"Front Oncol"},{"key":"2295_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C\u2013mutated advanced pancreatic cancer. N Engl J Med. 2023;388:33\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2208470.","journal-title":"N Engl J Med"},{"key":"2295_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071205","volume":"17","author":"N Gorbokon","year":"2025","unstructured":"Gorbokon N, Teljuk K, Reiswich V, et al. Deficiency of MTAP is frequent and mostly homogeneous in pancreatic ductal adenocarcinomas. Cancers. 2025;17:1205. https:\/\/doi.org\/10.3390\/cancers17071205.","journal-title":"Cancers"},{"key":"2295_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-20-3141","volume":"27","author":"SA V\u00e4yrynen","year":"2021","unstructured":"V\u00e4yrynen SA, Zhang J, Yuan C, et al. Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer. Clin Cancer Res. 2021;27:1069\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3141.","journal-title":"Clin Cancer Res"},{"key":"2295_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582\u201398. https:\/\/doi.org\/10.1038\/nrc.2016.73.","journal-title":"Nat Rev Cancer"},{"key":"2295_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/0008-5472.CAN-18-1334","volume":"79","author":"KY Elahi-Gedwillo","year":"2019","unstructured":"Elahi-Gedwillo KY, Carlson M, Zettervall J, Provenzano PP. Antifibrotic therapy disrupts stromal barriers and modulates the immune landscape in pancreatic ductal adenocarcinoma. Cancer Res. 2019;79:372\u201386. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1334.","journal-title":"Cancer Res"},{"key":"2295_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny B, Semenisty V, Macarulla T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26:878\u201385. https:\/\/doi.org\/10.1038\/s41591-020-0880-x.","journal-title":"Nat Med"},{"key":"2295_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ctrv.2019.06.005","volume":"78","author":"A Henriksen","year":"2019","unstructured":"Henriksen A, Dyhl-Polk A, Chen I, Nielsen D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev. 2019;78:17\u201330. https:\/\/doi.org\/10.1016\/j.ctrv.2019.06.005.","journal-title":"Cancer Treat Rev"},{"key":"2295_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38:1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105.","journal-title":"J Clin Oncol"},{"key":"2295_CR15","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DDV Hoff","year":"2013","unstructured":"Hoff DDV, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"key":"2295_CR16","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"key":"2295_CR17","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402:1272\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(23)01366-1.","journal-title":"Lancet"},{"key":"2295_CR18","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","volume":"25","author":"R Herrmann","year":"2007","unstructured":"Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212\u20137. https:\/\/doi.org\/10.1200\/JCO.2006.09.0886.","journal-title":"J Clin Oncol"},{"key":"2295_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.21037\/jgo.2016.01.03","volume":"7","author":"W Scheithauer","year":"2016","unstructured":"Scheithauer W, Ramanathan RK, Moore M, et al. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016;7:469\u201378. https:\/\/doi.org\/10.21037\/jgo.2016.01.03.","journal-title":"J Gastrointest Oncol"},{"key":"2295_CR20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.2025.43.4_suppl.716","volume":"43","author":"AJ Patel","year":"2025","unstructured":"Patel AJ, Laursen AA, Cockrum P, et al. Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: a post hoc analysis of NAPOLI 3. J Clin Oncol. 2025;43:716\u2013716. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.716.","journal-title":"J Clin Oncol"},{"key":"2295_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer Oxf Engl. 2019;108:78\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.007.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"2295_CR22","unstructured":"NCCN Clinical Practice Guidelines in Oncology: pancreatic adenocarcinoma. In: NCCN. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1455. Accessed 1 Oct 2025."},{"key":"2295_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","volume":"7","author":"DPS Sohal","year":"2021","unstructured":"Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7:421\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7328.","journal-title":"JAMA Oncol"},{"key":"2295_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:157\u201368. https:\/\/doi.org\/10.1016\/S2468-1253(22)00348-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2295_CR25","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC Trial. J Clin Oncol. 2022;40:1220\u201330. https:\/\/doi.org\/10.1200\/JCO.21.02233.","journal-title":"J Clin Oncol"},{"key":"2295_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","volume":"9","author":"KJ Labori","year":"2024","unstructured":"Labori KJ, Bratlie SO, Andersson B, et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024;9:205\u201317. https:\/\/doi.org\/10.1016\/S2468-1253(23)00405-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2295_CR27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809775","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/NEJMoa1809775.","journal-title":"N Engl J Med"},{"key":"2295_CR28","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1016\/S0140-6736(25)01685-X","volume":"406","author":"M Reni","year":"2026","unstructured":"Reni M, Macchini M, Orsi G, et al. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2\u2009\u00d7\u20092 factorial phase 3 trial. Lancet. 2026;406:2945\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(25)01685-X.","journal-title":"Lancet"},{"key":"2295_CR29","doi-asserted-by":"publisher","first-page":"LBA4004","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4004","volume":"43","author":"M Reni","year":"2025","unstructured":"Reni M, Macchini M, Orsi G, et al. Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma. J Clin Oncol. 2025;43:LBA4004\u2013LBA4004. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA4004.","journal-title":"J Clin Oncol"},{"key":"2295_CR30","unstructured":"Cancer Trial Results. https:\/\/clin.larvol.com\/feeds. Accessed 7 Nov 2025."},{"key":"2295_CR31","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jamaoncol.2025.0460","volume":"11","author":"M Reyngold","year":"2025","unstructured":"Reyngold M, Schoenfeld JD, O\u2019Reilly EM, et al. Nonoperative management of technically resectable pancreatic cancer with ablative radiation therapy. JAMA Oncol. 2025;11:609\u201316. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0460.","journal-title":"JAMA Oncol"},{"key":"2295_CR32","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1470-2045(23)00344-3","volume":"24","author":"T Leal","year":"2023","unstructured":"Leal T, Kotecha R, Ramlau R, et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol. 2023;24:1002\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(23)00344-3.","journal-title":"Lancet Oncol"},{"key":"2295_CR33","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1200\/JCO-25-00746","volume":"43","author":"HM Babiker","year":"2025","unstructured":"Babiker HM, Picozzi V, Chandana SR, et al. Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase III PANOVA-3 study. J Clin Oncol. 2025;43:2350\u201360. https:\/\/doi.org\/10.1200\/JCO-25-00746.","journal-title":"J Clin Oncol"},{"key":"2295_CR34","doi-asserted-by":"publisher","unstructured":"Knox JJ, O\u2019Kane G, King D, et al (2025) PASS-01: Randomized phase II trial of modified FOLFIRINOX versus gemcitabine\/nab-paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer. J Clin Oncol 0:JCO-25-00436. https:\/\/doi.org\/10.1200\/JCO-25-00436.","DOI":"10.1200\/JCO-25-00436"},{"key":"2295_CR35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00936","volume":"0","author":"A Ohba","year":"2025","unstructured":"Ohba A, Ozaka M, Mizusawa J, et al. Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin or s-1, irinotecan, and oxaliplatin versus nab-paclitaxel + gemcitabine in metastatic or recurrent pancreatic cancer (GENERATE, JCOG1611): a randomized, open-label, phase II\/III trial. J Clin Oncol. 2025;0:JCO.24.00936. https:\/\/doi.org\/10.1200\/JCO.24.00936.","journal-title":"J Clin Oncol"},{"key":"2295_CR36","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168\u201378. https:\/\/doi.org\/10.1038\/ng.3398.","journal-title":"Nat Genet"},{"key":"2295_CR37","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","volume":"26","author":"GM O\u2019Kane","year":"2020","unstructured":"O\u2019Kane GM, Gr\u00fcnwald BT, Jang G-H, et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res. 2020;26:4901\u201310. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3724.","journal-title":"Clin Cancer Res"},{"key":"2295_CR38","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1200\/JCO.2024.42.16_suppl.4150","volume":"42","author":"RA Mc Laughlin","year":"2024","unstructured":"Mc Laughlin RA, Salvatore L, Barone D, et al. GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as a prognostic and predictive biomarker in the Canadian COMPASS trial and the Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS. J Clin Oncol. 2024;42:4150\u20134150. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4150.","journal-title":"J Clin Oncol"},{"key":"2295_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.trsl.2024.08.002","volume":"273","author":"MF Lansbergen","year":"2024","unstructured":"Lansbergen MF, Dings MPG, Manoukian P, et al. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. Transl Res. 2024;273:137\u201347. https:\/\/doi.org\/10.1016\/j.trsl.2024.08.002.","journal-title":"Transl Res"},{"key":"2295_CR40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.clcc.2015.05.005","volume":"14","author":"D Li","year":"2015","unstructured":"Li D, Capanu M, Yu KH, et al. Treatment, outcomes, and clinical trial participation in elderly patients with metastatic pancreas adenocarcinoma. Clin Colorectal Cancer. 2015;14:269-276.e1. https:\/\/doi.org\/10.1016\/j.clcc.2015.05.005.","journal-title":"Clin Colorectal Cancer"},{"key":"2295_CR41","doi-asserted-by":"publisher","first-page":"910","DOI":"10.21037\/jgo.2019.06.02","volume":"10","author":"A Petrillo","year":"2019","unstructured":"Petrillo A, Pappalardo A, Calabrese F, et al. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. J Gastrointest Oncol. 2019;10:910\u20137. https:\/\/doi.org\/10.21037\/jgo.2019.06.02.","journal-title":"J Gastrointest Oncol"},{"key":"2295_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/oncolo\/oyac028","volume":"27","author":"R Elias","year":"2022","unstructured":"Elias R, Cockrum P, Surinach A, et al. Real-world impact of age at diagnosis on treatment patterns and survival outcomes of patients with metastatic pancreatic ductal adenocarcinoma. Oncologist. 2022;27:469\u201375. https:\/\/doi.org\/10.1093\/oncolo\/oyac028.","journal-title":"Oncologist"},{"key":"2295_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf236","author":"M Wooster","year":"2025","unstructured":"Wooster M, May M, Agrawal P, et al. The impact of eligibility criteria on KRASG12C inhibitor trials in patients with NSCLC. J Natl Cancer Inst. 2025. https:\/\/doi.org\/10.1093\/jnci\/djaf236.","journal-title":"J Natl Cancer Inst"},{"key":"2295_CR44","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2024.42.16_suppl.4003","volume":"42","author":"E Dotan","year":"2024","unstructured":"Dotan E, Catalano PJ, Lenchik L, et al. A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-na\u00efve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186. J Clin Oncol. 2024;42:4003\u20134003. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4003.","journal-title":"J Clin Oncol"},{"key":"2295_CR45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1200\/JCO.18.00089","volume":"37","author":"T Macarulla","year":"2019","unstructured":"Macarulla T, Pazo-Cid R, Guill\u00e9n-Ponce C, et al. Phase I\/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2. J Clin Oncol. 2019;37:230\u20138. https:\/\/doi.org\/10.1200\/JCO.18.00089.","journal-title":"J Clin Oncol"},{"key":"2295_CR46","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/oncolo\/oyad315","volume":"29","author":"JK Jamison","year":"2024","unstructured":"Jamison JK, May MS, Raufi AG, et al. A somatic BRCA2-mutated pancreatic adenocarcinoma with sustained exceptional response to modified FOLFIRINOX. Oncologist. 2024;29:350\u20135. https:\/\/doi.org\/10.1093\/oncolo\/oyad315.","journal-title":"Oncologist"},{"key":"2295_CR47","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","volume":"26","author":"W Park","year":"2020","unstructured":"Park W, Chen J, Chou JF, et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26:3239\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0418.","journal-title":"Clin Cancer Res"},{"key":"2295_CR48","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. J Clin Oncol. 2020;38:1378\u201388. https:\/\/doi.org\/10.1200\/JCO.19.02931.","journal-title":"J Clin Oncol"},{"key":"2295_CR49","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1706450.","journal-title":"N Engl J Med"},{"key":"2295_CR50","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa1911440.","journal-title":"N Engl J Med"},{"key":"2295_CR51","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1810858.","journal-title":"N Engl J Med"},{"key":"2295_CR52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1903387.","journal-title":"N Engl J Med"},{"key":"2295_CR53","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.21.00003","volume":"39","author":"KA Reiss","year":"2021","unstructured":"Reiss KA, Mick R, O\u2019Hara MH, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39:2497\u2013505. https:\/\/doi.org\/10.1200\/JCO.21.00003.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2295_CR54","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","volume":"7","author":"M Javle","year":"2021","unstructured":"Javle M, Shacham-Shmueli E, Xiao L, et al. Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: findings from 2 Phase 2 nonrandomized clinical trials. JAMA Oncol. 2021;7:693\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0006.","journal-title":"JAMA Oncol"},{"key":"2295_CR55","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1200\/JCO.2018.36.4_suppl.297","volume":"36","author":"T Golan","year":"2018","unstructured":"Golan T, Varadhachary GR, Sela T, et al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. J Clin Oncol. 2018;36:297\u2013297. https:\/\/doi.org\/10.1200\/JCO.2018.36.4_suppl.297.","journal-title":"J Clin Oncol"},{"key":"2295_CR56","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu ZI, Shia J, Stadler ZK, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res. 2018;24:1326\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3099.","journal-title":"Clin Cancer Res"},{"key":"2295_CR57","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00648","author":"R Ali-Fehmi","year":"2024","unstructured":"Ali-Fehmi R, Krause HB, Morris RT, et al. Analysis of concordance between next-generation sequencing assessment of microsatellite instability and immunohistochemistry-mismatch repair from solid tumors. JCO Precis Oncol. 2024. https:\/\/doi.org\/10.1200\/PO.23.00648.","journal-title":"JCO Precis Oncol"},{"key":"2295_CR58","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1001\/jamaoncol.2024.3651","volume":"10","author":"CA O\u2019Connor","year":"2024","unstructured":"O\u2019Connor CA, Harrold E, Lin D, et al. Lynch syndrome and somatic mismatch repair variants in pancreas cancer. JAMA Oncol. 2024;10:1511\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3651.","journal-title":"JAMA Oncol"},{"key":"2295_CR59","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00706","author":"T Coston","year":"2023","unstructured":"Coston T, Desai A, Babiker H, et al. Efficacy of immune checkpoint inhibition and cytotoxic chemotherapy in mismatch repair-deficient and microsatellite instability-high pancreatic cancer: Mayo clinic experience. JCO Precis Oncol. 2023. https:\/\/doi.org\/10.1200\/PO.22.00706.","journal-title":"JCO Precis Oncol"},{"key":"2295_CR60","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2023.04.012","volume":"188","author":"J Ta\u00efeb","year":"2023","unstructured":"Ta\u00efeb J, Sayah L, Heinrich K, et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European cohort. Eur J Cancer. 2023;188:90\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2023.04.012.","journal-title":"Eur J Cancer"},{"key":"2295_CR61","doi-asserted-by":"publisher","first-page":"458","DOI":"10.21037\/jgo-22-587","volume":"14","author":"MY Han","year":"2023","unstructured":"Han MY, Borazanci E. A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report. J Gastrointest Oncol. 2023;14:458\u201362. https:\/\/doi.org\/10.21037\/jgo-22-587.","journal-title":"J Gastrointest Oncol"},{"key":"2295_CR62","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","volume":"28","author":"GD Demetri","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res. 2022;28:1302\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3597.","journal-title":"Clin Cancer Res"},{"key":"2295_CR63","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(19)30856-3.","journal-title":"Lancet Oncol"},{"key":"2295_CR64","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol. 2022;23:1261\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(22)00541-1.","journal-title":"Lancet Oncol"},{"key":"2295_CR65","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1200\/JCO.2024.42.3_suppl.746","volume":"42","author":"V Subbiah","year":"2024","unstructured":"Subbiah V, Drilon AE, Sukrithan V, et al. Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001. J Clin Oncol. 2024;42:746\u2013746. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.746.","journal-title":"J Clin Oncol"},{"key":"2295_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01044-y","volume":"9","author":"S Xiang","year":"2025","unstructured":"Xiang S, Zheng Y, Wang M, et al. Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors. NPJ Precis Oncol. 2025;9:262. https:\/\/doi.org\/10.1038\/s41698-025-01044-y.","journal-title":"NPJ Precis Oncol"},{"key":"2295_CR67","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa2405008","volume":"392","author":"AM Schram","year":"2025","unstructured":"Schram AM, Goto K, Kim D-W, et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med. 2025;392:566\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2405008.","journal-title":"N Engl J Med"},{"key":"2295_CR68","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/2159-8290.CD-18-0036","volume":"8","author":"C Heining","year":"2018","unstructured":"Heining C, Horak P, Uhrig S, et al. NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer Discov. 2018;8:1087\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0036.","journal-title":"Cancer Discov"},{"key":"2295_CR69","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/onco.13800","volume":"26","author":"M May","year":"2021","unstructured":"May M, Raufi AG, Sadeghi S, et al. Prolonged response to HER2-directed therapy in three patients with HER2-amplified metastatic carcinoma of the biliary system: case study and review of the literature. Oncologist. 2021;26:640\u20136. https:\/\/doi.org\/10.1002\/onco.13800.","journal-title":"Oncologist"},{"key":"2295_CR70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42:47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005.","journal-title":"J Clin Oncol"},{"key":"2295_CR71","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1200\/JCO.20.00762","volume":"38","author":"AKS Salama","year":"2020","unstructured":"Salama AKS, Li S, Macrae ER, et al. Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H. J Clin Oncol. 2020;38:3895\u2013904. https:\/\/doi.org\/10.1200\/JCO.20.00762.","journal-title":"J Clin Oncol"},{"key":"2295_CR72","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00684","author":"MI Ebia","year":"2025","unstructured":"Ebia MI, Blais EM, Cui Y, et al. Evaluating the effect of KRAS variants on survival outcomes and therapy response in pancreatic cancer. JCO Precis Oncol. 2025. https:\/\/doi.org\/10.1200\/PO-24-00684.","journal-title":"JCO Precis Oncol"},{"key":"2295_CR73","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","volume":"12","author":"MH Hofmann","year":"2022","unstructured":"Hofmann MH, Gerlach D, Misale S, et al. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 2022;12:924\u201337. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1331.","journal-title":"Cancer Discov"},{"key":"2295_CR74","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351. https:\/\/doi.org\/10.1038\/nature12796.","journal-title":"Nature"},{"key":"2295_CR75","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-ND11","volume":"82","author":"H Purkey","year":"2022","unstructured":"Purkey H. Abstract ND11: discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers. Cancer Res. 2022;82:ND11. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-ND11.","journal-title":"Cancer Res"},{"key":"2295_CR76","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher A, LoRusso P, Patel MR, et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023;389:710\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2303810.","journal-title":"N Engl J Med"},{"key":"2295_CR77","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2024.42.16_suppl.3007","volume":"42","author":"RS Heist","year":"2024","unstructured":"Heist RS, Koyama T, Murciano-Goroff YR, et al. Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors. J Clin Oncol. 2024;42:3007\u20133007. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3007.","journal-title":"J Clin Oncol"},{"key":"2295_CR78","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS. Nat Med. 2024;30:969\u201383. https:\/\/doi.org\/10.1038\/s41591-024-02903-0.","journal-title":"Nat Med"},{"key":"2295_CR79","doi-asserted-by":"publisher","first-page":"12287","DOI":"10.1021\/acs.jmedchem.5c01441","volume":"68","author":"Z Ma","year":"2025","unstructured":"Ma Z, Zhou M, Shen Q, Zhou J. RAS(ON) therapies on the horizon to address KRAS resistance: highlight on a phase III clinical candidate daraxonrasib (RMC-6236). J Med Chem. 2025;68:12287\u201392. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01441.","journal-title":"J Med Chem"},{"key":"2295_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104250","volume":"30","author":"P Filis","year":"2025","unstructured":"Filis P, Salgkamis D, Matikas A, Zerdes I. Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236. Drug Discov Today. 2025;30:104250. https:\/\/doi.org\/10.1016\/j.drudis.2024.104250.","journal-title":"Drug Discov Today"},{"key":"2295_CR81","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1200\/JCO.2025.43.4_suppl.722","volume":"43","author":"I Garrido-Laguna","year":"2025","unstructured":"Garrido-Laguna I, Wolpin BM, Park W, et al. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2025;43:722\u2013722. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.722.","journal-title":"J Clin Oncol"},{"key":"2295_CR82","unstructured":"Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma | Revolution Medicines. https:\/\/ir.revmed.com\/news-releases\/news-release-details\/revolution-medicines-shares-new-clinical-results-supporting\/. Accessed 7 Oct 2025."},{"key":"2295_CR83","unstructured":"Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy | Revolution Medicines. https:\/\/ir.revmed.com\/news-releases\/news-release-details\/revolution-medicines-announces-first-patient-randomized-rasolute\/. Accessed 15 Jan 2026."},{"key":"2295_CR84","unstructured":"Revolution Medicines, Inc. RASolute 304: a phase 3 multicenter, open-label, randomized, 2-arm study of adjuvant daraxonrasib versus standard of care observation following completion of neoadjuvant and\/or adjuvant chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC). 2025. http:\/\/clinicaltrials.gov."},{"key":"2295_CR85","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","volume":"9","author":"MN Zeissig","year":"2023","unstructured":"Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends Cancer. 2023;9:955\u201367. https:\/\/doi.org\/10.1016\/j.trecan.2023.07.010.","journal-title":"Trends Cancer"},{"key":"2295_CR86","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1200\/JCO.2025.43.16_suppl.3013","volume":"43","author":"X Ai","year":"2025","unstructured":"Ai X, Zhou A, Wu L, et al. A first-in-human phase I\/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors. J Clin Oncol. 2025;43:3013\u20133013. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3013.","journal-title":"J Clin Oncol"},{"key":"2295_CR87","unstructured":"helenabradbury (2025) ESMO 2025: GFH375 shows potential against KRAS G12D pancreatic tumours. In: Eur. Med. J. https:\/\/www.emjreviews.com\/oncology\/news\/esmo-2025-gfh375-shows-potential-against-kras-g12d-pancreatic-tumours\/. Accessed 7 Nov 2025."},{"key":"2295_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2832","volume":"36","author":"L Wang","year":"2025","unstructured":"Wang L, Jiang K, Li W, et al. 2215o HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D mutant advanced pancreatic cancer: a phase Ib\/II study. Ann Oncol. 2025;36:S1231. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2832.","journal-title":"Ann Oncol"},{"key":"2295_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s42004-025-01662-4","volume":"8","author":"T Yoshinari","year":"2025","unstructured":"Yoshinari T, Nagashima T, Ishioka H, et al. Discovery of KRAS(G12D) selective degrader ASP3082. Commun Chem. 2025;8:254. https:\/\/doi.org\/10.1038\/s42004-025-01662-4.","journal-title":"Commun Chem"},{"key":"2295_CR90","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.675","volume":"35","author":"W Park","year":"2024","unstructured":"Park W, Kasi A, Spira AI, et al. 608O preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC). Ann Oncol. 2024;35:S486\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.675.","journal-title":"Ann Oncol"},{"key":"2295_CR91","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka N, Lin JJ, Li C, et al. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS\u2013MAPK reactivation. Cancer Discov. 2021;11:1913\u201322. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0365.","journal-title":"Cancer Discov"},{"key":"2295_CR92","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Murciano-Goroff YR, Xue JY, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021;599:679\u201383. https:\/\/doi.org\/10.1038\/s41586-021-04065-2.","journal-title":"Nature"},{"key":"2295_CR93","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRASG12C inhibition in cancer. N Engl J Med. 2021;384:2382\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2105281.","journal-title":"N Engl J Med"},{"key":"2295_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51828-2","volume":"15","author":"M-J Nokin","year":"2024","unstructured":"Nokin M-J, Mira A, Patrucco E, et al. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. Nat Commun. 2024;15:7554. https:\/\/doi.org\/10.1038\/s41467-024-51828-2.","journal-title":"Nat Commun"},{"key":"2295_CR95","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41388-023-02676-9","volume":"42","author":"J Feng","year":"2023","unstructured":"Feng J, Hu Z, Xia X, et al. Feedback activation of EGFR\/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. Oncogene. 2023;42:1620\u201333. https:\/\/doi.org\/10.1038\/s41388-023-02676-9.","journal-title":"Oncogene"},{"key":"2295_CR96","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022;28:2171\u201382. https:\/\/doi.org\/10.1038\/s41591-022-02007-7.","journal-title":"Nat Med"},{"key":"2295_CR97","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","volume":"5","author":"EA Chapeau","year":"2024","unstructured":"Chapeau EA, Sansregret L, Galli GG, et al. Direct and selective pharmacological disruption of the YAP\u2013TEAD interface by IAG933 inhibits Hippo-dependent and RAS\u2013MAPK-altered cancers. Nat Cancer. 2024;5:1102\u201320. https:\/\/doi.org\/10.1038\/s43018-024-00754-9.","journal-title":"Nat Cancer"},{"key":"2295_CR98","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, Jiang L, Maldonato BJ, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14:994\u20131017. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0027.","journal-title":"Cancer Discov"},{"key":"2295_CR99","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1158\/2159-8290.CD-24-0421","volume":"14","author":"HA Araujo","year":"2024","unstructured":"Araujo HA, Pechuan-Jorge X, Zhou T, et al. Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant non\u2013small cell lung cancer. Cancer Discov. 2024;14:2183\u2013208. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0421.","journal-title":"Cancer Discov"},{"key":"2295_CR100","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko UN, Jiang J, Dalton TC, et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature. 2024;629:927\u201336. https:\/\/doi.org\/10.1038\/s41586-024-07379-z.","journal-title":"Nature"},{"key":"2295_CR101","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman MT, Abbassi L, et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 2024;14:2135\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0177.","journal-title":"Cancer Discov"},{"key":"2295_CR102","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022;23:115\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(21)00605-7.","journal-title":"Lancet Oncol"},{"key":"2295_CR103","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;389:2125\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2308795.","journal-title":"N Engl J Med"},{"key":"2295_CR104","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;388:44\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2212419.","journal-title":"N Engl J Med"},{"key":"2295_CR105","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y, et al. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21:354\u201369. https:\/\/doi.org\/10.1038\/s41571-024-00874-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"2295_CR106","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"key":"2295_CR107","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"2295_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165394","volume":"12","author":"S Park","year":"2023","unstructured":"Park S, Shin K, Kim I-H, et al. Clinicopathological features and prognosis of resected pancreatic ductal adenocarcinoma patients with claudin-18 overexpression. J Clin Med. 2023;12:5394. https:\/\/doi.org\/10.3390\/jcm12165394.","journal-title":"J Clin Med"},{"key":"2295_CR109","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.4251\/wjgo.v14.i7.1252","volume":"14","author":"X Wang","year":"2022","unstructured":"Wang X, Zhang C-S, Dong X-Y, et al. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol. 2022;14:1252\u201364. https:\/\/doi.org\/10.4251\/wjgo.v14.i7.1252.","journal-title":"World J Gastrointest Oncol"},{"key":"2295_CR110","unstructured":"Astellas Confirms Phase 2 GLEAM trial did not meet primary endpoint of overall survival in patients with metastatic pancreatic cancer. In: Astellas Glob. https:\/\/newsroom.astellas.com\/2025-10-13-Astellas-Confirms-Phase-2-GLEAM-Trial-Did-Not-Meet-Primary-Endpoint-of-Overall-Survival-in-Patients-with-Metastatic-Pancreatic-Cancer. Accessed 27 Oct 2025."},{"key":"2295_CR111","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2023.41.16_suppl.3016","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Gong J, Lin R, et al. First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant\/refractory solid tumors. J Clin Oncol. 2023;41:3016\u20133016. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3016.","journal-title":"J Clin Oncol"},{"key":"2295_CR112","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-SITC2024.1500","author":"Y Wang","year":"2024","unstructured":"Wang Y, Gong J, Qu X, Shen L. 1500 A phase II trial of bispecific antibody Q-1802 in patients with relapsed or refractory solid tumors. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.1500.","journal-title":"J Immunother Cancer"},{"key":"2295_CR113","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1200\/JCO.23.02314","volume":"42","author":"C Qi","year":"2024","unstructured":"Qi C, Zhang P, Liu C, et al. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials. J Clin Oncol. 2024;42:2565\u201377. https:\/\/doi.org\/10.1200\/JCO.23.02314.","journal-title":"J Clin Oncol"},{"key":"2295_CR114","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1158\/2159-8290.CD-24-0740","volume":"14","author":"A Singhal","year":"2024","unstructured":"Singhal A, Styers HC, Rub J, et al. A classical epithelial state drives acute resistance to KRAS inhibition in pancreatic cancer. Cancer Discov. 2024;14:2122\u201334. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0740.","journal-title":"Cancer Discov"},{"key":"2295_CR115","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/annonc\/mdu205","volume":"25","author":"M Aglietta","year":"2014","unstructured":"Aglietta M, Barone C, Sawyer MB, et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol. 2014;25:1750\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdu205.","journal-title":"Ann Oncol"},{"key":"2295_CR116","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly EM, Oh D-Y, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1431\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1588.","journal-title":"JAMA Oncol"},{"key":"2295_CR117","doi-asserted-by":"publisher","first-page":"e15281","DOI":"10.1200\/jco.2015.33.15_suppl.e15281","volume":"33","author":"NA Mohindra","year":"2015","unstructured":"Mohindra NA, Kircher SM, Nimeiri HS, et al. Results of the phase Ib study of ipilimumab and gemcitabine for advanced pancreas cancer. J Clin Oncol. 2015;33:e15281\u2013e15281. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.e15281.","journal-title":"J Clin Oncol"},{"key":"2295_CR118","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature. 2025;639:1042\u201351. https:\/\/doi.org\/10.1038\/s41586-024-08508-4.","journal-title":"Nature"},{"key":"2295_CR119","unstructured":"Genentech, Inc. A phase II, open-label, multicenter, randomized study of the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and mFOLFIRINOX versus mFOLFIRINOX alone in patients with resected pancreatic ductal adenocarcinoma. 2025. http:\/\/clinicaltrials.gov."},{"key":"2295_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2025.101049","author":"BP Conn","year":"2025","unstructured":"Conn BP, Dietze JL, Yee CJ, et al. Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell Rep Methods. 2025. https:\/\/doi.org\/10.1016\/j.crmeth.2025.101049.","journal-title":"Cell Rep Methods"},{"key":"2295_CR121","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature12978","volume":"507","author":"H Liu","year":"2014","unstructured":"Liu H, Moynihan KD, Zheng Y, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507:519\u201322. https:\/\/doi.org\/10.1038\/nature12978.","journal-title":"Nature"},{"key":"2295_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03876-4","author":"ZA Wainberg","year":"2025","unstructured":"Wainberg ZA, Weekes CD, Furqan M, et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03876-4.","journal-title":"Nat Med"},{"key":"2295_CR123","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/annonc\/mdz200","volume":"30","author":"B Lee","year":"2019","unstructured":"Lee B, Lipton L, Cohen J, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol. 2019;30:1472\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz200.","journal-title":"Ann Oncol"},{"key":"2295_CR124","unstructured":"Elicio Therapeutics. First in Human Phase 1\/2 Trial of ELI-002 7P immunotherapy as treatment for subjects with Kirsten Rat Sarcoma (KRAS)\/neuroblastoma RAS viral oncogene homolog (NRAS) mutated pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. 2025. http:\/\/clinicaltrials.gov."},{"key":"2295_CR125","doi-asserted-by":"publisher","first-page":"28960","DOI":"10.1073\/pnas.2013644117","volume":"117","author":"D Biasci","year":"2020","unstructured":"Biasci D, Smoragiewicz M, Connell CM, et al. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci USA. 2020;117:28960\u201370. https:\/\/doi.org\/10.1073\/pnas.2013644117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2295_CR126","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20212\u20137. https:\/\/doi.org\/10.1073\/pnas.1320318110.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2295_CR127","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","volume":"27","author":"B Bockorny","year":"2021","unstructured":"Bockorny B, Macarulla T, Semenisty V, et al. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT\/KEYNOTE-202 trial. Clin Cancer Res. 2021;27:5020\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0929.","journal-title":"Clin Cancer Res"},{"key":"2295_CR128","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/sj.bjc.6605968","volume":"103","author":"S Singh","year":"2010","unstructured":"Singh S, Srivastava SK, Bhardwaj A, et al. CXCL12\u2013CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer. 2010;103:1671\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6605968.","journal-title":"Br J Cancer"},{"key":"2295_CR129","doi-asserted-by":"publisher","unstructured":"Manji GA, May M, Chalabi MH, et al (2024) Abstract PR05: CheMo4METPANC: combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (c-x-c) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in METastatic treatment-na\u00efve PANCreatic adenocarcinoma. Cancer Res 84:PR05. https:\/\/doi.org\/10.1158\/1538-7445.PANCA2023-PR05.","DOI":"10.1158\/1538-7445.PANCA2023-PR05"},{"key":"2295_CR130","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1200\/JCO.2025.43.16_suppl.4167","volume":"43","author":"GA Manji","year":"2025","unstructured":"Manji GA, May MS, D\u2019Souza EK, et al. CheMo4METPANC: combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-na\u00efve pancreatic adenocarcinoma\u2014updated clinical and translational findings. J Clin Oncol. 2025;43:4167\u20134167. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4167.","journal-title":"J Clin Oncol"},{"key":"2295_CR131","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4208","volume":"42","author":"GA Manji","year":"2024","unstructured":"Manji GA, May MS, Chalabi M, et al. CheMo4METPANC: a randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-na\u00efve pancreatic adenocarcinoma. J Clin Oncol. 2024;42:TPS4208\u2013TPS4208. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS4208.","journal-title":"J Clin Oncol"},{"key":"2295_CR132","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/1535-7163.MCT-21-0802","volume":"21","author":"D Piovesan","year":"2022","unstructured":"Piovesan D, Tan JBL, Becker A, et al. Targeting CD73 with AB680 (Quemliclustat), a novel and potent small-molecule CD73 inhibitor, restores immune functionality and facilitates antitumor immunity. Mol Cancer Ther. 2022;21:948\u201359. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0802.","journal-title":"Mol Cancer Ther"},{"key":"2295_CR133","doi-asserted-by":"publisher","DOI":"10.1158\/1538-8514.CANCERCHEM24-PR003","volume":"23","author":"J Jeffrey","year":"2024","unstructured":"Jeffrey J. Structure-guided design and optimization of small molecule CD73 inhibitors with excellent drug-like properties: discovery of quemliclustat. Mol Cancer Ther. 2024;23:PR003. https:\/\/doi.org\/10.1158\/1538-8514.CANCERCHEM24-PR003.","journal-title":"Mol Cancer Ther"},{"key":"2295_CR134","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1200\/JCO.2024.42.3_suppl.665","volume":"42","author":"ZA Wainberg","year":"2024","unstructured":"Wainberg ZA, Manji GA, Bahary N, et al. ARC-8: Phase 1\/1b randomized study of quemliclustat + gemcitabine\/nab-paclitaxel \u00b1 zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma. J Clin Oncol. 2024;42:665\u2013665. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.665.","journal-title":"J Clin Oncol"},{"key":"2295_CR135","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1016\/j.annonc.2025.05.399","volume":"36","author":"TM Mercade","year":"2025","unstructured":"Mercade TM, Bekaii-Saab T, Feeney K, et al. 384TiP quemliclustat and chemotherapy in previously untreated patients with metastatic pancreatic ductal adenocarcinoma: PRISM-1, a randomized, placebo-controlled, phase III trial. Ann Oncol. 2025;36:S147\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.399.","journal-title":"Ann Oncol"},{"key":"2295_CR136","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612\u20136. https:\/\/doi.org\/10.1126\/science.1198443.","journal-title":"Science"},{"key":"2295_CR137","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","volume":"25","author":"J-L Van Laethem","year":"2024","unstructured":"Van Laethem J-L, Borbath I, Prenen H, et al. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study. Lancet Oncol. 2024;25:853\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(24)00263-8.","journal-title":"Lancet Oncol"},{"key":"2295_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201069","author":"M Esteves","year":"2025","unstructured":"Esteves M, Matos AM, Cruz MT. Oncolytic viruses: anovel therapeutic approach for pancreatic cancer. Mol Ther Oncol. 2025. https:\/\/doi.org\/10.1016\/j.omton.2025.201069.","journal-title":"Mol Ther Oncol"},{"key":"2295_CR139","doi-asserted-by":"publisher","first-page":"S1146","DOI":"10.1016\/j.annonc.2025.08.2833","volume":"36","author":"R Garcia-Carbonero","year":"2025","unstructured":"Garcia-Carbonero R, Cid RAP, Mercade TM, et al. 2216MO virage trial: randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with\/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC). Ann Oncol. 2025;36:S1146\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2833.","journal-title":"Ann Oncol"},{"key":"2295_CR140","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS719","volume":"42","author":"A Kasi","year":"2024","unstructured":"Kasi A, Phadnis MA, Al-Rajabi RMT, et al. A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC). J Clin Oncol. 2024;42:TPS719\u2013TPS719. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.TPS719.","journal-title":"J Clin Oncol"},{"key":"2295_CR141","doi-asserted-by":"publisher","first-page":"S1237","DOI":"10.1016\/j.annonc.2025.08.2842","volume":"36","author":"W Ren","year":"2025","unstructured":"Ren W, Park W, Yu X, et al. 2225P Tissue factor (TF) antibody-drug conjugate (ADC) MRG004A in patients (pts) with advanced pancreatic cancer (PC): updated results from a phase I study. Ann Oncol. 2025;36:S1237. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2842.","journal-title":"Ann Oncol"},{"key":"2295_CR142","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.2024.42.16_suppl.3002","volume":"42","author":"W Park","year":"2024","unstructured":"Park W, Zhang J, Dayyani F, et al. Phase I\/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors. J Clin Oncol. 2024;42:3002\u20133002. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3002.","journal-title":"J Clin Oncol"},{"key":"2295_CR143","unstructured":"Lepu Moves Pancreatic Cancer ADC to Phase III. In: PharmCube. https:\/\/global.pharmcube.com\/news\/detail\/cda3be15849a44e7b54c200bf00746d0?type=dailyNews. Accessed 28 Oct 2025."},{"key":"2295_CR144","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1158\/2767-9764.CRC-23-0546","volume":"4","author":"CD Miller","year":"2024","unstructured":"Miller CD, Lozada JR, Zorko NA, et al. Pan-cancer interrogation of B7-H3 (CD276) as an actionable therapeutic target across human malignancies. Cancer Res Commun. 2024;4:1369\u201379. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0546.","journal-title":"Cancer Res Commun"},{"key":"2295_CR145","unstructured":"MacroGenics. A phase 1, open-label, dose escalation study of MGA271 in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors. 2022. http:\/\/clinicaltrials.gov."},{"key":"2295_CR146","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","volume":"29","author":"E Shenderov","year":"2023","unstructured":"Shenderov E, De Marzo AM, Lotan TL, et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med. 2023;29:888\u201397. https:\/\/doi.org\/10.1038\/s41591-023-02284-w.","journal-title":"Nat Med"},{"key":"2295_CR147","doi-asserted-by":"publisher","first-page":"53","DOI":"10.36401\/JIPO-23-18","volume":"7","author":"K Feustel","year":"2024","unstructured":"Feustel K, Martin J, Falchook GS. B7-H3 inhibitors in oncology clinical trials: a review. J Immunother Precis Oncol. 2024;7:53\u201366. https:\/\/doi.org\/10.36401\/JIPO-23-18.","journal-title":"J Immunother Precis Oncol"},{"key":"2295_CR148","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/d41573-025-00027-9","volume":"24","author":"A Mullard","year":"2025","unstructured":"Mullard A. FDA approves TROP2-targeted antibody\u2013drug conjugate for breast cancer. Nat Rev Drug Discov. 2025;24:159\u2013159. https:\/\/doi.org\/10.1038\/d41573-025-00027-9.","journal-title":"Nat Rev Drug Discov"},{"key":"2295_CR149","doi-asserted-by":"publisher","first-page":"TPS846","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS846","volume":"43","author":"MJ Pishvaian","year":"2025","unstructured":"Pishvaian MJ, Yoshino T, Weekes CD, et al. Phase 1\/2 study of the trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy or combination therapy in gastrointestinal cancers: LIGHTBEAM-02A. J Clin Oncol. 2025;43:TPS846\u2013TPS846. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.TPS846.","journal-title":"J Clin Oncol"},{"key":"2295_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02839-w","volume":"22","author":"G Wu","year":"2022","unstructured":"Wu G, Li L, Liu M, et al. Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. Cancer Cell Int. 2022;22:417. https:\/\/doi.org\/10.1186\/s12935-022-02839-w.","journal-title":"Cancer Cell Int"},{"key":"2295_CR151","doi-asserted-by":"publisher","first-page":"e15025","DOI":"10.1200\/JCO.2024.42.16_suppl.e15025","volume":"42","author":"R Ahmad","year":"2024","unstructured":"Ahmad R, Panchamoorthy G, Raina D, et al. Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment. J Clin Oncol. 2024;42:e15025\u2013e15025. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e15025.","journal-title":"J Clin Oncol"},{"key":"2295_CR152","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18632\/genesandcancer.230","volume":"14","author":"J Thomas","year":"2023","unstructured":"Thomas J, Klebanov A, John S, et al. CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens. Genes Cancer. 2023;14:12\u201329. https:\/\/doi.org\/10.18632\/genesandcancer.230.","journal-title":"Genes Cancer"},{"key":"2295_CR153","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1200\/JCO.2025.43.16_suppl.4018","volume":"43","author":"RW Lentz","year":"2025","unstructured":"Lentz RW, Ng MCH, Yong W-P, et al. Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study. J Clin Oncol. 2025;43:4018\u20134018. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4018.","journal-title":"J Clin Oncol"},{"key":"2295_CR154","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.21037\/jgo-23-85","volume":"14","author":"H Tan","year":"2023","unstructured":"Tan H, Hosein PJ. Detection and therapeutic implications of homologous recombination repair deficiency in pancreatic cancer: a narrative review. J Gastrointest Oncol. 2023;14:2249\u201359. https:\/\/doi.org\/10.21037\/jgo-23-85.","journal-title":"J Gastrointest Oncol"},{"key":"2295_CR155","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1053\/j.gastro.2021.01.220","volume":"160","author":"T Golan","year":"2021","unstructured":"Golan T, O\u2019Kane GM, Denroche RE, et al. Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma. Gastroenterology. 2021;160:2119-2132.e9. https:\/\/doi.org\/10.1053\/j.gastro.2021.01.220.","journal-title":"Gastroenterology"},{"key":"2295_CR156","unstructured":"National Cancer Institute (NCI). APOLLO: a randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation. 2025. http:\/\/clinicaltrials.gov."},{"key":"2295_CR157","doi-asserted-by":"publisher","DOI":"10.1007\/s12609-025-00582-5","volume":"17","author":"A Ray","year":"2025","unstructured":"Ray A, Opyrchal M. Targeting PARP1: a promising approach for next-generation poly (ADP-ribose) polymerase inhibitors. Curr Breast Cancer Rep. 2025;17:22. https:\/\/doi.org\/10.1007\/s12609-025-00582-5.","journal-title":"Curr Breast Cancer Rep"},{"key":"2295_CR158","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-CT007","volume":"82","author":"TA Yap","year":"2022","unstructured":"Yap TA, Im S-A, Schram AM, et al. Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations. Cancer Res. 2022;82:CT007. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-CT007.","journal-title":"Cancer Res"},{"key":"2295_CR159","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s13577-021-00630-z","volume":"35","author":"C Yang","year":"2022","unstructured":"Yang C, Zhang Z, Tang X, et al. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders. Hum Cell. 2022;35:199\u2013213. https:\/\/doi.org\/10.1007\/s13577-021-00630-z.","journal-title":"Hum Cell"},{"key":"2295_CR160","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/1759-7714.15408","volume":"15","author":"A Gao","year":"2024","unstructured":"Gao A, Wang X, Wang J, et al. Homologous recombination deficiency status predicts response to immunotherapy-based treatment in non-small cell lung cancer patients. Thorac Cancer. 2024;15:1842\u201353. https:\/\/doi.org\/10.1111\/1759-7714.15408.","journal-title":"Thorac Cancer"},{"key":"2295_CR161","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/jamaoncol.2022.0611","volume":"8","author":"G Terrero","year":"2022","unstructured":"Terrero G, Datta J, Dennison J, et al. Ipilimumab\/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants. JAMA Oncol. 2022;8:938\u201340. https:\/\/doi.org\/10.1001\/jamaoncol.2022.0611.","journal-title":"JAMA Oncol"},{"key":"2295_CR162","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1200\/JCO.2023.41.16_suppl.4140","volume":"41","author":"W Park","year":"2023","unstructured":"Park W, O\u2019Connor C, Chou JF, et al. Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy. J Clin Oncol. 2023;41:4140\u20134140. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.4140.","journal-title":"J Clin Oncol"},{"key":"2295_CR163","doi-asserted-by":"publisher","unstructured":"Park W, O\u2019Connor C, Chou J, et al. Pembrolizumab and olaparib (POLAR) maintenance therapy in metastatic pancreatic cancer with or without homologous repair deficiency: a biomarker selected phase II Trial. Res Sq rs.3.rs-7334701. 2025. https:\/\/doi.org\/10.21203\/rs.3.rs-7334701\/v1.","DOI":"10.21203\/rs.3.rs-7334701\/v1"},{"key":"2295_CR164","doi-asserted-by":"publisher","first-page":"TPS447","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS447","volume":"39","author":"V Chung","year":"2021","unstructured":"Chung V, Guthrie KA, Pishvaian MJ, et al. Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1\/2+) mutations: SWOG S2001. J Clin Oncol. 2021;39:TPS447\u2013TPS447. https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.TPS447.","journal-title":"J Clin Oncol"},{"key":"2295_CR165","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.716467","volume":"11","author":"V Conteduca","year":"2021","unstructured":"Conteduca V, Scarpi E, Farolfi A, et al. Melphalan as a promising treatment for BRCA-related ovarian carcinoma. Front Oncol. 2021;11:716467. https:\/\/doi.org\/10.3389\/fonc.2021.716467.","journal-title":"Front Oncol"},{"key":"2295_CR166","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/jcp.2010.086405","volume":"64","author":"DJ Osher","year":"2011","unstructured":"Osher DJ, Kushner YB, Arseneau J, Foulkes WD. Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks? J Clin Pathol. 2011;64:924\u20136. https:\/\/doi.org\/10.1136\/jcp.2010.086405.","journal-title":"J Clin Pathol"},{"key":"2295_CR167","doi-asserted-by":"publisher","first-page":"TPS774","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS774","volume":"41","author":"KH Yu","year":"2023","unstructured":"Yu KH, Weekes CD, Chen Y-BA, et al. The SHARON trial: a study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation. J Clin Oncol. 2023;41:TPS774\u2013TPS774. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.TPS774.","journal-title":"J Clin Oncol"},{"key":"2295_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2845","volume":"36","author":"KH Yu","year":"2025","unstructured":"Yu KH, Dahi P, Weekes CD, et al. 2228P the SHARON trial: melphalan, BCNU, hydroxocobalamin, ascorbic acid, and stem cells for pancreatic and breast cancer and an inherited BRCA\/PALB2 mutation. Ann Oncol. 2025;36:S1238. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2845.","journal-title":"Ann Oncol"},{"key":"2295_CR169","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1126\/science.aar5149","volume":"359","author":"GS Higgins","year":"2018","unstructured":"Higgins GS, Boulton SJ. Beyond PARP\u2014POL\u03b8 as an anticancer target. Science. 2018;359:1217\u20138. https:\/\/doi.org\/10.1126\/science.aar5149.","journal-title":"Science"},{"key":"2295_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46593-1","volume":"15","author":"W Fried","year":"2024","unstructured":"Fried W, Tyagi M, Minakhin L, et al. Discovery of a small-molecule inhibitor that traps Pol\u03b8 on DNA and synergizes with PARP inhibitors. Nat Commun. 2024;15:2862. https:\/\/doi.org\/10.1038\/s41467-024-46593-1.","journal-title":"Nat Commun"},{"key":"2295_CR171","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","volume":"2","author":"J Zhou","year":"2021","unstructured":"Zhou J, Gelot C, Pantelidou C, et al. A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors. Nat Cancer. 2021;2:598\u2013610. https:\/\/doi.org\/10.1038\/s43018-021-00203-x.","journal-title":"Nat Cancer"},{"key":"2295_CR172","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT169","volume":"84","author":"V Samnotra","year":"2024","unstructured":"Samnotra V, Moroz V, Shtessel L, et al. Abstract CT169: first-in-human, phase 1\/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors. Cancer Res. 2024;84:CT169. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-CT169.","journal-title":"Cancer Res"},{"key":"2295_CR173","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1158\/0008-5472.CAN-20-0414","volume":"81","author":"Q Hu","year":"2021","unstructured":"Hu Q, Qin Y, Ji S, et al. MTAP deficiency\u2013induced metabolic reprogramming creates a vulnerability to cotargeting de novo purine synthesis and glycolysis in pancreatic cancer. Cancer Res. 2021;81:4964\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-0414.","journal-title":"Cancer Res"},{"key":"2295_CR174","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","volume":"15","author":"B Belmontes","year":"2025","unstructured":"Belmontes B, Slemmons KK, Su C, et al. AMG 193, a Clinical stage MTA-cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-deleted cancers. Cancer Discov. 2025;15:139\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0887.","journal-title":"Cancer Discov"},{"key":"2295_CR175","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204978","volume":"15","author":"B Vrugt","year":"2023","unstructured":"Vrugt B, Kirschner MB, Meerang M, et al. Deletions of CDKN2A and MTAP detected by copy-number variation array are associated with loss of p16 and MTAP protein in pleural mesothelioma. Cancers. 2023;15:4978. https:\/\/doi.org\/10.3390\/cancers15204978.","journal-title":"Cancers"},{"key":"2295_CR176","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnen\/nlab127","volume":"81","author":"S Sasaki","year":"2022","unstructured":"Sasaki S, Takeda M, Hirose T, et al. Correlation of MTAP immunohistochemistry with CDKN2A status assessed by fluorescence in situ hybridization and clinicopathological features in CNS WHO grade 2 and 3 meningiomas: a single center cohort study. J Neuropathol Exp Neurol. 2022;81:117\u201326. https:\/\/doi.org\/10.1093\/jnen\/nlab127.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2295_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104535","author":"H Ikushima","year":"2025","unstructured":"Ikushima H, Watanabe K, Shinozaki-Ushiku A, et al. Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data. ESMO Open. 2025. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104535.","journal-title":"ESMO Open"},{"key":"2295_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2025.100966","volume":"44","author":"MC Clouser","year":"2025","unstructured":"Clouser MC, Suh M, Movva N, et al. A systematic literature review of MTAP deletions in solid and hematologic cancers. Cancer Treat Res Commun. 2025;44:100966. https:\/\/doi.org\/10.1016\/j.ctarc.2025.100966.","journal-title":"Cancer Treat Res Commun"},{"key":"2295_CR179","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1021\/acs.jmedchem.4c03067","volume":"68","author":"KM Cottrell","year":"2025","unstructured":"Cottrell KM, Briggs KJ, Tsai A, et al. Discovery of TNG462: a highly potent and selective MTA-cooperative PRMT5 inhibitor to target cancers with MTAP deletion. J Med Chem. 2025;68:5097\u2013119. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c03067.","journal-title":"J Med Chem"},{"key":"2295_CR180","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","volume":"35","author":"J Rodon","year":"2024","unstructured":"Rodon J, Prenen H, Sacher A, et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration\u2606. Ann Oncol. 2024;35:1138\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2339.","journal-title":"Ann Oncol"},{"key":"2295_CR181","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1200\/JCO.2025.43.16_suppl.3011","volume":"43","author":"KC Arbour","year":"2025","unstructured":"Arbour KC, George B, Henry JT, et al. BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion ( MTAP -del): clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007. J Clin Oncol. 2025;43:3011\u20133011. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3011.","journal-title":"J Clin Oncol"},{"key":"2295_CR182","unstructured":"Tango Therapeutics Reports Positive Data from Ongoing Phase 1\/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers | Tango Therapeutics, Inc. https:\/\/ir.tangotx.com\/news-releases\/news-release-details\/tango-therapeutics-reports-positive-data-ongoing-phase-12-study\/. Accessed 28 Oct 2025."},{"key":"2295_CR183","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-2996","volume":"85","author":"M Zhang","year":"2025","unstructured":"Zhang M, Tsai A, Cottrell KM, et al. Abstract 2996: TNG462, an MTA-cooperative PRMT5 inhibitor, demonstrates strong efficacy in combination with clinically relevant targeted therapies in MTAP-null preclinical models. Cancer Res. 2025;85:2996. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-2996.","journal-title":"Cancer Res"},{"key":"2295_CR184","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01732-6","volume":"39","author":"C Luchini","year":"2020","unstructured":"Luchini C, Paolino G, Mattiolo P, et al. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J Exp Clin Cancer Res. 2020;39:227. https:\/\/doi.org\/10.1186\/s13046-020-01732-6.","journal-title":"J Exp Clin Cancer Res"},{"key":"2295_CR185","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, K\u00f6hne C-H, L\u00e1ng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.33.5091.","journal-title":"J Clin Oncol"},{"key":"2295_CR186","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/annonc\/mdt270","volume":"24","author":"H Fensterer","year":"2013","unstructured":"Fensterer H, Schade-Brittinger C, M\u00fcller H-H, et al. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Ann Oncol. 2013;24:2576\u201381. https:\/\/doi.org\/10.1093\/annonc\/mdt270.","journal-title":"Ann Oncol"},{"key":"2295_CR187","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1093\/annonc\/mdx343","volume":"28","author":"B Schultheis","year":"2017","unstructured":"Schultheis B, Reuter D, Ebert MP, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:2429\u201335. https:\/\/doi.org\/10.1093\/annonc\/mdx343.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2295_CR188","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1200\/JCO.22.02630","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin S, Li J, Bai Y, et al. Nimotuzumab plus gemcitabine for k-ras wild-type locally advanced or metastatic pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41:5163\u201373. https:\/\/doi.org\/10.1200\/JCO.22.02630.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2295_CR189","unstructured":"SWOG Cancer Research Network. Randomized phase III study of second-line chemotherapy with or without panitumumab for KRAS wild type, locally advanced or metastatic pancreatic adenocarcinoma. 2025. http:\/\/clinicaltrials.gov."},{"key":"2295_CR190","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1200\/JCO.24.00081","volume":"42","author":"EB Ludmir","year":"2024","unstructured":"Ludmir EB, Sherry AD, Fellman BM, et al. Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): a multicenter, randomized phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42:3795\u2013805. https:\/\/doi.org\/10.1200\/JCO.24.00081.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2295_CR191","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1038\/s41588-025-02345-5","volume":"57","author":"M Chalabi Hajkarim","year":"2025","unstructured":"Chalabi Hajkarim M, May M, Amin AD, et al. Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. Nat Genet. 2025;57:2728\u201342. https:\/\/doi.org\/10.1038\/s41588-025-02345-5.","journal-title":"Nat Genet"},{"key":"2295_CR192","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/07357907.2023.2203747","volume":"41","author":"MS May","year":"2023","unstructured":"May MS, Jamison JK, Wong W, et al. Smoking is not associated with lung metastasis in pancreatic cancer. Cancer Invest. 2023;41:487\u201390. https:\/\/doi.org\/10.1080\/07357907.2023.2203747.","journal-title":"Cancer Invest"},{"key":"2295_CR193","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/jhbp.1127","volume":"29","author":"Y Homma","year":"2022","unstructured":"Homma Y, Endo I, Matsuyama R, et al. Outcomes of lung metastasis from pancreatic cancer: a nationwide multicenter analysis. J Hepatobiliary Pancreat Sci. 2022;29:552\u201361. https:\/\/doi.org\/10.1002\/jhbp.1127.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2295_CR194","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.pan.2021.01.014","volume":"21","author":"C He","year":"2021","unstructured":"He C, Huang X, Zhang Y, et al. The impact of different metastatic patterns on survival in patients with pancreatic cancer. Pancreatology. 2021;21:556\u201363. https:\/\/doi.org\/10.1016\/j.pan.2021.01.014.","journal-title":"Pancreatology"},{"key":"2295_CR195","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000551","volume":"51","author":"M Nakajima","year":"2017","unstructured":"Nakajima M, Ueno T, Suzuki N, et al. Novel indications for surgical resection of metachronous lung metastases from pancreatic cancer after curative resection. J Clin Gastroenterol. 2017;51:e34. https:\/\/doi.org\/10.1097\/MCG.0000000000000551.","journal-title":"J Clin Gastroenterol"},{"key":"2295_CR196","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-023-03198-4","volume":"409","author":"T Konishi","year":"2023","unstructured":"Konishi T, Takano S, Takayashiki T, et al. Clinical benefits of pulmonary resection for lung metastases from pancreatic cancer. Langenbecks Arch Surg. 2023;409:11. https:\/\/doi.org\/10.1007\/s00423-023-03198-4.","journal-title":"Langenbecks Arch Surg"},{"key":"2295_CR197","doi-asserted-by":"publisher","first-page":"326","DOI":"10.5090\/kjtcs.2017.50.5.326","volume":"50","author":"M Okui","year":"2017","unstructured":"Okui M, Yamamichi T, Asakawa A, et al. Resection for pancreatic cancer lung metastases. Korean J Thorac Cardiovasc Surg. 2017;50:326\u20138. https:\/\/doi.org\/10.5090\/kjtcs.2017.50.5.326.","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"2295_CR198","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/j.lpm.2019.02.032","volume":"48","author":"A-L V\u00e9die","year":"2019","unstructured":"V\u00e9die A-L, Neuzillet C. Pancreatic cancer: best supportive care. Presse Med. 2019;48:e175\u201385. https:\/\/doi.org\/10.1016\/j.lpm.2019.02.032.","journal-title":"Presse Med"},{"key":"2295_CR199","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1002\/cncr.32423","volume":"125","author":"GT Moffat","year":"2019","unstructured":"Moffat GT, Epstein AS, O\u2019Reilly EM. Pancreatic cancer\u2014a disease in need: optimizing and integrating supportive care. Cancer. 2019;125:3927\u201335. https:\/\/doi.org\/10.1002\/cncr.32423.","journal-title":"Cancer"},{"key":"2295_CR200","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1093\/jnci\/djaf139","volume":"117","author":"F Keane","year":"2025","unstructured":"Keane F, Saadat LV, O\u2019Connor CA, et al. Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. J Natl Cancer Inst. 2025;117:1848\u201357. https:\/\/doi.org\/10.1093\/jnci\/djaf139.","journal-title":"J Natl Cancer Inst"},{"key":"2295_CR201","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044238","volume":"24","author":"AG Raufi","year":"2023","unstructured":"Raufi AG, May MS, Hadfield MJ, et al. Advances in liquid biopsy technology and implications for pancreatic cancer. Int J Mol Sci. 2023;24:4238. https:\/\/doi.org\/10.3390\/ijms24044238.","journal-title":"Int J Mol Sci"},{"key":"2295_CR202","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/annonc\/mdp332","volume":"21","author":"MJ Duffy","year":"2010","unstructured":"Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdp332.","journal-title":"Ann Oncol"},{"key":"2295_CR203","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2200075.","journal-title":"N Engl J Med"},{"key":"2295_CR204","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie J, Wang Y, Lo SN, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31:1509\u201318. https:\/\/doi.org\/10.1038\/s41591-025-03579-w.","journal-title":"Nat Med"},{"key":"2295_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051124","volume":"13","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Esmail A, Hassanain H, et al. Correlative analysis of tumor-informed circulating tumor DNA (ctDNA) and the survival outcomes of patients with pancreatic adenocarcinoma. Biomedicines. 2025;13:1124. https:\/\/doi.org\/10.3390\/biomedicines13051124.","journal-title":"Biomedicines"},{"key":"2295_CR206","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/oncolo\/oyae155","volume":"29","author":"GP Botta","year":"2024","unstructured":"Botta GP, Abdelrahim M, Drengler RL, et al. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Oncologist. 2024;29:859\u201369. https:\/\/doi.org\/10.1093\/oncolo\/oyae155.","journal-title":"Oncologist"},{"key":"2295_CR207","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65562-8","volume":"14","author":"T Theparee","year":"2024","unstructured":"Theparee T, Akroush M, Sabatini LM, et al. Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlations. Sci Rep. 2024;14:15744. https:\/\/doi.org\/10.1038\/s41598-024-65562-8.","journal-title":"Sci Rep"},{"key":"2295_CR208","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-024-01151-2","volume":"56","author":"P Jonnalagadda","year":"2025","unstructured":"Jonnalagadda P, Arnold V, Weinberg BA. A review of circulating tumor DNA (ctDNA) in pancreatic cancer: ready for the clinic? J Gastrointest Cancer. 2025;56:50. https:\/\/doi.org\/10.1007\/s12029-024-01151-2.","journal-title":"J Gastrointest Cancer"},{"key":"2295_CR209","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/JCO.2024.42.16_suppl.107","volume":"42","author":"B Lee","year":"2024","unstructured":"Lee B, Tie J, Wang Y, et al. The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: the AGITG DYNAMIC-Pancreas trial. J Clin Oncol. 2024;42:107\u2013107. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.107.","journal-title":"J Clin Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02295-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:00:58Z","timestamp":1774069258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02295-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":209,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2295"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02295-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MSM acknowledges funding through the following: ASCO Conquer Cancer Young Investigator Award (2024YIA-2215472755), NCI K38 career development award (1K38CA304069-01), Cancer Center Support Grant\/Core Grant P30 CA008748. WP acknowledges funding through the following: research funding to Institution: NIH\/NCI SPORE Pancreas (P50 CA257881-01A1), Paul Calabresi Career Development Award for Clinical Oncology (K12 CA184746), Cancer Center Support Grant\/Core Grant (P30 CA008748), Break Through Cancer, Parker Institute for Cancer Immunotherapy, The Society of MSK, Merck, Astellas, Lepu Biopharma, Amgen, Revolution Medicines. Consulting: Astellas, EXACT Therapeutics, Revolution Medicines, Innovent Biologics, Regeneron Pharmaceuticals, KeyQuest, TD Cowen, Alphasights, CME honoraria: American Physician Institute, Curio, Integrity, Physicians' Education Resource, Aptitude Health, Travel Fee from Amgen and DAVA Oncology. EOR acknowledges funding through the following: research Funding to Institution: Genentech\/Roche, BioNTech, AstraZeneca, Arcus, Elicio Therapeutics, Parker Institute, NIH\/NCI, Digestive Care, Break Through Cancer, Agenus, Amgen, Revolution Medicines, Tango Therapeutics. Consulting\/DSMB: Uncompensated: Arcus, Amgen, AstraZeneca, Alligator BioSciences, Pfizer, Agenus, BioNTech, Ipsen, Ikena, Merck, Immuneering, Moma Therapeutics, Novartis, Astellas, BMS, Revolution Medicines, Regeneron, Tango Therapeutics. Travel: BioNTech, Arcus. Other: American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Imedex, Research To Practice, Stand Up To Cancer (SU2C), NIH\/NCI Cancer Center Support Grant\/Core Grant P30 CA008748, NCI\/NIH P50 CA257881-01A1.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MM, WP, EOR designed, authored, reviewed, and approved the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}